Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Prelude Therapeutics ( (PRLD) ).
On April 20, 2026, Prelude Therapeutics announced the pricing of an underwritten public offering of 18,018,014 shares of common stock at $4.44 per share and pre-funded warrants for up to 2,252,252 additional shares at $4.4399 each. The transaction, led by Goldman Sachs, Evercore ISI and Citizens Capital Markets, is expected to generate approximately $90 million in gross proceeds, or about $85.5 million in net proceeds after fees and expenses.
The deal, which was led by new investor RA Capital Management with participation from Soleus Capital and other healthcare-focused investors, is expected to close on or about April 21, 2026, subject to customary conditions. Prelude plans to use the capital to support general corporate purposes, including research and the preclinical and clinical development of its oncology product candidates, extending its projected cash runway into the second quarter of 2028 and strengthening its financial position for ongoing pipeline advancement.
The most recent analyst rating on (PRLD) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.
Spark’s Take on PRLD Stock
According to Spark, TipRanks’ AI Analyst, PRLD is a Neutral.
The score is held back primarily by weak financial performance (large ongoing losses, negative free cash flow, and declining equity/assets). This is partially offset by strong technical momentum (price above major moving averages with positive MACD) and supportive recent corporate milestones (IND clearance and encouraging preclinical updates), while valuation remains constrained by the negative P/E and lack of dividend support.
To see Spark’s full report on PRLD stock, click here.
More about Prelude Therapeutics
Prelude Therapeutics Incorporated is a clinical-stage precision oncology company focused on developing innovative medicines for cancer patients with high unmet need. Its pipeline includes highly selective KAT6A degraders, JAK2V617F mutant-selective inhibitors, and next-generation degrader antibody conjugates, targeting clinically validated pathways with the aim of broadening the reach of precision medicine in oncology.
The company leverages its expertise in targeted protein degradation and small-molecule design to build a differentiated portfolio in solid tumors and hematologic malignancies. By concentrating on novel mechanisms and selective targeting, Prelude seeks to position itself within the competitive oncology landscape as a specialist in next-generation precision therapies.
Average Trading Volume: 300,683
Technical Sentiment Signal: Buy
Current Market Cap: $347.8M
For detailed information about PRLD stock, go to TipRanks’ Stock Analysis page.